MWNA
UBX

Marshall Wace North America’s Unity Biotechnology UBX Stock Holding History

Marshall Wace North America’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$43K Hold
1,440
– – ﹤0.01% 1384
2021
Q2 		$67K Buy
+1,440
New +$69.3K ﹤0.01% 1392
2020
Q2 		– Sell
-964
Closed -$56K – 1490
2020
Q1 		$56K Hold
964
– – ﹤0.01% 1063
2019
Q4 		$70K Sell
964
-179
-16% -$12.6K ﹤0.01% 1106
2019
Q3 		$70K Buy
+1,143
New +$80.9K ﹤0.01% 1112

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace North America's UBX Position: Q3 2021 in Review

Marshall Wace North America held its Unity Biotechnology (UBX) position steady in Q3 2021 at 1,440 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #1384.

Marshall Wace North America first reported a position in UBX in Q3 2019 and has held it in 5 quarters since. The position peaked at $70K in Q4 2019. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

  • Marshall Wace North America held 1,440 shares of Unity Biotechnology worth $43K as of Q3 2021.
  • Marshall Wace North America left its Unity Biotechnology share count unchanged in Q3 2021.
  • Unity Biotechnology made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1384 holding.
  • Marshall Wace North America first reported a position in Unity Biotechnology in Q3 2019 and has held it in 5 quarters since.
  • Marshall Wace North America's Unity Biotechnology position peaked at $70K in Q4 2019.
  • 84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.